| pubmed-article:20975250 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C0740457 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C0229473 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C1176020 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C0439662 | lld:lifeskim |
| pubmed-article:20975250 | lifeskim:mentions | umls-concept:C1515021 | lld:lifeskim |
| pubmed-article:20975250 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20975250 | pubmed:dateCreated | 2011-2-17 | lld:pubmed |
| pubmed-article:20975250 | pubmed:abstractText | Sunitinib is standard first-line therapy for metastatic clear cell renal cancer (MCRC). It is associated with leucopenia; however, its effects on specific immune cell subsets are unclear. Alterations in immune cell subsets may contribute to tumour progression. | lld:pubmed |
| pubmed-article:20975250 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20975250 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20975250 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20975250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20975250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20975250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20975250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20975250 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20975250 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20975250 | pubmed:issn | 1423-0399 | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:BowerMarkM | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:ChowdhurySimo... | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:GreenJamesJ | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:SarwarNaveedN | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:ShamashJonath... | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:PetersJohnJ | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:PowlesThomasT | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:LimLouiseL | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:BoletiKatiaK | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:SaundersNatai... | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:SadevAnjuA | lld:pubmed |
| pubmed-article:20975250 | pubmed:author | pubmed-author:AugwalSamirS | lld:pubmed |
| pubmed-article:20975250 | pubmed:copyrightInfo | Copyright © 2010 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:20975250 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20975250 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:20975250 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20975250 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20975250 | pubmed:pagination | 53-9 | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:meshHeading | pubmed-meshheading:20975250... | lld:pubmed |
| pubmed-article:20975250 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20975250 | pubmed:articleTitle | The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. | lld:pubmed |
| pubmed-article:20975250 | pubmed:affiliation | St Bartholomew Hospital, London, UK. thomas.powles@bartsandthelondon.nhs.uk | lld:pubmed |
| pubmed-article:20975250 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20975250 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:20975250 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
